Search research articles
Contact Us
Filters
Showing results (1-10 of 15) with videos related to
Page
of 2
Sort By:
Circulation
|
June 20, 2003
Proceedings of the 99th meeting of the Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee. May 29th and 30th, 2003
Jeffrey Borer, Paul Armstrong,
Circulation
|
May 9, 2002
Losartan potassium (Cozaar)
JoAnn Lindenfeld, Jeffrey Borer, Paul W Armstrong
Circulation
|
August 7, 2002
Candesartan
Paul W Armstrong, Beverly H Lorell, Steven Nissen, et al.
Circulation
|
August 22, 2002
Pravastatin and Aspirin
Paul W Armstrong, Beverly H Lorell, Steven Nissen, et al.
Circulation
|
August 22, 2002
Omapatrilat
Paul W Armstrong, Beverly H Lorell, Steven Nissen, et al.
Journal of the American College of Cardiology
|
May 24, 2012
Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study
Karl Swedberg, Michel Komajda, Michael Böhm, et al.
Fundamental & Clinical Pharmacology
|
August 12, 2010
Surrogate endpoints in randomized cardiovascular clinical trials
Michael Domanski, Stuart Pocock, Corine Bernaud, et al.
European Journal of Heart Failure
|
August 16, 2012
Influence of background treatment with mineralocorticoid receptor antagonists on ivabradine's effects in patients with chronic heart failure
Michel Komajda, Michael Böhm, Jeffrey Borer, et al.
European Journal of Heart Failure
|
May 23, 2013
Impact of left bundle branch block on heart rate and its relationship to treatment with ivabradine in chronic heart failure
Jan-Christian Reil, Michele Robertson, Ian Ford, et al.
European Journal of Heart Failure
|
June 20, 2017
Heart rate and its reduction in chronic heart failure and beyond
Aleksandra Nikolovska Vukadinović, Davor Vukadinović, Jeffrey Borer, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 15) with videos related to
Sort By:
Page
of 2
Circulation
|
June 20, 2003
Proceedings of the 99th meeting of the Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee. May 29th and 30th, 2003
Jeffrey Borer, Paul Armstrong,
Circulation
|
May 9, 2002
Losartan potassium (Cozaar)
JoAnn Lindenfeld, Jeffrey Borer, Paul W Armstrong
Circulation
|
August 7, 2002
Candesartan
Paul W Armstrong, Beverly H Lorell, Steven Nissen, et al.
Circulation
|
August 22, 2002
Pravastatin and Aspirin
Paul W Armstrong, Beverly H Lorell, Steven Nissen, et al.
Circulation
|
August 22, 2002
Omapatrilat
Paul W Armstrong, Beverly H Lorell, Steven Nissen, et al.
Journal of the American College of Cardiology
|
May 24, 2012
Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study
Karl Swedberg, Michel Komajda, Michael Böhm, et al.
Fundamental & Clinical Pharmacology
|
August 12, 2010
Surrogate endpoints in randomized cardiovascular clinical trials
Michael Domanski, Stuart Pocock, Corine Bernaud, et al.
European Journal of Heart Failure
|
August 16, 2012
Influence of background treatment with mineralocorticoid receptor antagonists on ivabradine's effects in patients with chronic heart failure
Michel Komajda, Michael Böhm, Jeffrey Borer, et al.
European Journal of Heart Failure
|
May 23, 2013
Impact of left bundle branch block on heart rate and its relationship to treatment with ivabradine in chronic heart failure
Jan-Christian Reil, Michele Robertson, Ian Ford, et al.
European Journal of Heart Failure
|
June 20, 2017
Heart rate and its reduction in chronic heart failure and beyond
Aleksandra Nikolovska Vukadinović, Davor Vukadinović, Jeffrey Borer, et al.
Page
of 2